Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998.
Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998, according to a recent report released by Newtown, PA-based Scott-Levin.
For the 12 months ending October 1998, psychiatrists received more than 58 million visits - an increase of 4% over the year before.
As a result of those consultations, they wrote 93.1 million retail prescriptions, or 1,815 prescriptions per doctor. That's 5% more prescriptions than the number psychiatrists wrote the year before. In total, psychiatrists were responsible for $5.6 billion in retail prescription sales.
"The main fact could be that psychiatrists have had a lot more attention lately from specialty sales forces. They are receiving a lot more details, mainly due to the companies' strategies," said Andrew Diefes, a marketing research analyst for Scott-Levin, when asked why psychiatrists were writing a greater volume of prescriptions.
According to Scott-Levin, the top products prescribed by psychiatrists were the same drugs that were most detailed. Prozac accounted for 8.1% of prescriptions, Zoloft received 5.4% of prescriptions and Paxil accounted for 5% of prescriptions.
By therapeutic class, the top five classes prescribed by psychiatrists were: specific neurotransmitter modulators, such as selective serotonin receptor inhibitors and selective NR inhibitors, (24.5%); seizure disorder therapies, (10.4%); antipsychotics, (9.5%); benzodiazepines, (9.3%); and similar antidepressants, (7.5%).
Sales reps made 2.6 million details to psychiatrists for the year ended October 1998, making psychiatrists the fifth most detailed group of doctors. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.